Alnylam Slides to 248th in Market Activity as Daily Volume Crumbles 31.89%

Alnylam Pharmaceuticals (ALNY) closed on September 18, 2025, , , . , reflecting reduced institutional engagement amid mixed sector dynamics. Analysts noted that the muted volume may indicate consolidation following recent therapeutic updates and regulatory timelines.

Recent developments highlighted include a partnership advancement in RNAi therapeutics, which reinforced long-term growth potential but did not trigger immediate trading enthusiasm. The company’s pipeline progress in rare disease treatments remains a key focus for investors, though near-term catalysts appear limited. Market participants are closely monitoring upcoming data readouts and potential collaborations in the gene therapy space.

To back-test “buy the top 500 stocks by daily trading volume, hold for one day,” practical parameters must be defined: universe scope, rebalancing methodology, transaction cost assumptions, and data coverage. Once finalized, , , , , 2022, , . Clarification on these details is required to proceed with data retrieval and analysis.